Viatris is no longer speaking about divestitures, so we may conclude that management are content with what's been achieved already and are looking to augment its products and pipeline with M&A ...

Viatris' earnings beat was driven by effective cost management. For fiscal 2024, analysts anticipate Viatris to report an EPS of $2.68, down 8.5% from $2.93 in fiscal 2023 .

Zooming in further, Viatris has lagged behind the SPDR S&P Pharmaceuticals ETF’s 6.3% gains over the past 52 weeks and 4.8% return in 2025. On Nov. 7, Viatris announced its third-quarter ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Shares of Viatris Inc. VTRS slipped 1.03% to $10.62 Monday, on what proved to be an all-around positive trading session for ...

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer patient ...

Viatris Inc. (VTRS), headquartered in Canonsburg, Pennsylvania, is a leading global healthcare company dedicated to empowering people worldwide to live healthier at every stage of life. With a ...

Shares of Viatris Inc. VTRS shed 0.33% to $11.96 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,918.25 ...